-DOCSTART- -X- O
Cancer -X- _ B-Intervention
therapy -X- _ I-Intervention
has -X- _ O
been -X- _ O
characterized -X- _ O
throughout -X- _ O
history -X- _ O
by -X- _ O
ups -X- _ O
and -X- _ O
downs -X- _ O
, -X- _ O
not -X- _ O
only -X- _ O
due -X- _ O
to -X- _ O
the -X- _ O
ineffectiveness -X- _ O
of -X- _ O
treatments -X- _ O
and -X- _ O
side -X- _ O
effects -X- _ O
, -X- _ O
but -X- _ O
also -X- _ O
by -X- _ O
hope -X- _ O
and -X- _ O
the -X- _ O
reality -X- _ O
of -X- _ O
complete -X- _ O
remission -X- _ O
and -X- _ O
cure -X- _ O
in -X- _ O
many -X- _ O
cases. -X- _ O
Within -X- _ O
the -X- _ O
therapeutic -X- _ O
arsenal -X- _ O
, -X- _ O
alongside -X- _ O
surgery -X- _ B-Intervention
in -X- _ O
the -X- _ O
case -X- _ O
of -X- _ O
solid -X- _ O
tumors -X- _ O
, -X- _ O
are -X- _ O
the -X- _ O
antitumor -X- _ O
drugs -X- _ O
and -X- _ O
radiation -X- _ B-Intervention
that -X- _ O
have -X- _ O
been -X- _ O
the -X- _ O
treatment -X- _ O
of -X- _ O
choice -X- _ O
in -X- _ O
some -X- _ O
instances. -X- _ O
In -X- _ O
recent -X- _ O
years -X- _ O
, -X- _ O
immunotherapy -X- _ B-Intervention
has -X- _ O
become -X- _ O
an -X- _ O
important -X- _ O
therapeutic -X- _ O
alternative -X- _ O
, -X- _ O
and -X- _ O
is -X- _ O
now -X- _ O
the -X- _ O
first -X- _ O
choice -X- _ O
in -X- _ O
many -X- _ O
cases. -X- _ O
Nanotechnology -X- _ B-Intervention
has -X- _ O
recently -X- _ O
arrived -X- _ O
on -X- _ O
the -X- _ O
scene -X- _ O
, -X- _ O
offering -X- _ O
nanostructures -X- _ O
as -X- _ O
new -X- _ O
therapeutic -X- _ O
alternatives -X- _ O
for -X- _ O
controlled -X- _ O
drug -X- _ O
delivery -X- _ O
, -X- _ O
for -X- _ O
combining -X- _ O
imaging -X- _ O
and -X- _ O
treatment -X- _ O
, -X- _ O
applying -X- _ O
hyperthermia -X- _ O
, -X- _ O
and -X- _ O
providing -X- _ O
directed -X- _ O
target -X- _ O
therapy -X- _ O
, -X- _ O
among -X- _ O
others. -X- _ O
These -X- _ O
therapies -X- _ O
can -X- _ O
be -X- _ O
applied -X- _ O
either -X- _ O
alone -X- _ B-Intervention
or -X- _ I-Intervention
in -X- _ I-Intervention
combination -X- _ I-Intervention
with -X- _ I-Intervention
other -X- _ I-Intervention
components -X- _ I-Intervention
( -X- _ I-Intervention
antibodies -X- _ I-Intervention
, -X- _ I-Intervention
peptides -X- _ I-Intervention
, -X- _ I-Intervention
folic -X- _ I-Intervention
acid -X- _ I-Intervention
, -X- _ I-Intervention
etc. -X- _ I-Intervention
) -X- _ I-Intervention
. -X- _ O
In -X- _ O
addition -X- _ O
, -X- _ O
gene -X- _ B-Intervention
therapy -X- _ I-Intervention
is -X- _ O
also -X- _ O
offering -X- _ O
promising -X- _ O
new -X- _ O
methods -X- _ O
for -X- _ O
treatment. -X- _ O
Here -X- _ O
, -X- _ O
we -X- _ O
present -X- _ O
a -X- _ O
review -X- _ O
of -X- _ O
the -X- _ O
evolution -X- _ O
of -X- _ O
cancer -X- _ O
treatments -X- _ O
, -X- _ O
starting -X- _ O
with -X- _ O
chemotherapy -X- _ B-Intervention
, -X- _ I-Intervention
surgery -X- _ I-Intervention
, -X- _ I-Intervention
radiation -X- _ I-Intervention
and -X- _ I-Intervention
immunotherapy -X- _ I-Intervention
, -X- _ I-Intervention
and -X- _ I-Intervention
moving -X- _ I-Intervention
on -X- _ I-Intervention
to -X- _ I-Intervention
the -X- _ I-Intervention
most -X- _ I-Intervention
promising -X- _ I-Intervention
cutting-edge -X- _ I-Intervention
therapies -X- _ I-Intervention
( -X- _ I-Intervention
gene -X- _ I-Intervention
therapy -X- _ I-Intervention
and -X- _ I-Intervention
nanomedicine -X- _ I-Intervention
) -X- _ I-Intervention
. -X- _ O
We -X- _ O
offer -X- _ O
an -X- _ O
historical -X- _ O
point -X- _ O
of -X- _ O
view -X- _ O
that -X- _ O
covers -X- _ O
the -X- _ O
arrival -X- _ O
of -X- _ O
these -X- _ O
therapies -X- _ O
to -X- _ O
clinical -X- _ O
practice -X- _ O
and -X- _ O
the -X- _ O
market -X- _ O
, -X- _ O
and -X- _ O
the -X- _ O
promises -X- _ O
and -X- _ O
challenges -X- _ O
they -X- _ O
present -X- _ O
. -X- _ O

